Symbol not found

:TBIO   00:00AM GMT
0.00
0.00 (0.00%)
Products, Regulatory, Earnings Announcements

Translate Bio Announces Results From Second Interim Data Analysis From Ongoing Phase 1/2 Clinical Trial Of MRT5005 In Patients With Cystic Fibrosis

Published: 03/17/2021 20:17 GMT
(TBIO) - Translate Bio Announces Results From Second Interim Data Analysis From Ongoing Phase 1/2 Clinical Trial of Mrt5005 in Patients With Cystic Fibrosis (cf).
Translate Bio Inc - First Inhaled Mrna Therapeutic Delivered in Multiple Doses to Lungs of Cf Patients is Generally Safe and Well Tolerated.
Translate Bio Inc - No Observed Pattern of Increases in Ppfev.
Translate Bio Inc - Phase 1/2 Clinical Trial for Mrt5005 Ongoing and Next-generation Cf Candidate Anticipated to Enter Ind-enabling Studies in 2h 2021.